Skip to main navigation Skip to search Skip to main content

Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials

  • VX20-121-102 Study Group
  • , VX20-121-103 Study Group

Research output: Contribution to journal › Article › peer-review

102   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science